Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa.

Boyd A, Kouamé MG, Houghtaling L, Moh R, Gabillard D, Maylin S, Abdou Chekaraou M, Delaugerre C, Anglaret X, Eholié SP, Danel C, Zoulim F, Lacombe K; ANRS 12136 Temprano and ANRS 12240 VarBVA studies.

Trans R Soc Trop Med Hyg. 2019 Aug 1;113(8):437-445. doi: 10.1093/trstmh/trz021.

PMID:
31574151
2.

Elevated fatty liver index as a risk factor for all-cause mortality in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study).

Barré T, Protopopescu C, Bani-Sadr F, Piroth L, Rojas Rojas T, Salmon-Ceron D, Wittkop L, Esterle L, Sogni P, Lacombe K, Chas J, Zaegel O, Chaix ML, Miailhes P, Serfaty L, Marcellin F, Carrieri MP; ANRS CO13 HEPAVIH Study Group.

Hepatology. 2019 Aug 29. doi: 10.1002/hep.30914. [Epub ahead of print]

PMID:
31466125
3.

Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international study.

Artenie AA, Cunningham EB, Dore GJ, Conway B, Dalgard O, Powis J, Bruggmann P, Hellard M, Cooper C, Read P, Feld JJ, Hajarizadeh B, Amin J, Lacombe K, Stedman C, Litwin AH, Marks P, Matthews GV, Quiene S, Erratt A, Bruneau J, Grebely J.

Clin Infect Dis. 2019 Jul 11. pii: ciz633. doi: 10.1093/cid/ciz633. [Epub ahead of print]

PMID:
31300820
4.

Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort.

Chalouni M, Sogni P, Miailhes P, Lacombe K, Poizot-Martin I, Chas J, Vittecoq D, Neau D, Aumaitre H, Alric L, Piroth L, Bouchaud O, Katlama C, Morlat P, Lascoux-Combe C, Gervais A, Naqvi A, Rosenthal E, Garipuy D, Barange K, Esterle L, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

Eur J Gastroenterol Hepatol. 2019 Nov;31(11):1387-1396. doi: 10.1097/MEG.0000000000001408.

PMID:
31033848
5.

"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study.

Gantner P, Sylla B, Morand-Joubert L, Frange P, Lacombe K, Khuong MA, Duvivier C, Launay O, Karmochkine M, Arvieux C, Ménard A, Piroth L, Canestri A, Trias D, Peytavin G, Landman R, Ghosn J; Coferal-IMEA048 Study Group.

PLoS One. 2019 Apr 24;14(4):e0216010. doi: 10.1371/journal.pone.0216010. eCollection 2019.

6.

[Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach].

Paccoud O, Surgers L, Lacombe K.

Rev Med Interne. 2019 Sep;40(9):590-598. doi: 10.1016/j.revmed.2019.03.333. Epub 2019 Apr 11. French.

PMID:
30982550
7.

Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.

Shili-Masmoudi S, Sogni P, de Ledinghen V, Esterle L, Valantin MA, Poizot-Martin I, Simon A, Rosenthal E, Lacombe K, Pialoux G, Bouchaud O, Gervais-Hasenknoff A, Goujard C, Piroth L, Zucman D, Dominguez S, Raffi F, Alric L, Bani-Sadr F, Lascoux-Combe C, Garipuy D, Miailhes P, Vittecoq D, Duvivier C, Aumaître H, Neau D, Morlat P, Dabis F, Salmon D, Wittkop L; ANRS CO13 HEPAVIH study group.

PLoS One. 2019 Jan 25;14(1):e0211286. doi: 10.1371/journal.pone.0211286. eCollection 2019.

8.

Chlamydia trachomatis screening in urine among asymptomatic men attending an STI clinic in Paris: a cross-sectional study.

Rondeau P, Valin N, Decré D, Girard PM, Lacombe K, Surgers L.

BMC Infect Dis. 2019 Jan 8;19(1):31. doi: 10.1186/s12879-018-3595-6.

9.

Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort.

Billa O, Chalouni M, Salmon D, Poizot-Martin I, Gilbert C, Katlama C, Neau D, Chas J, Morlat P, Lacombe K, Naqvi A, Barange K, Gervais A, Bouchaud O, Rosenthal E, Lascoux-Combe C, Garipuy D, Alric L, Dominguez S, Vittecoq D, Goujard C, Duvivier C, Aumaitre H, Miailhes P, Zucman D, Simon A, Lazaro E, Raffi F, Esterle L, Wittkop L, Bani-Sadr F; ANRS CO13 HEPAVIH Study Group.

PLoS One. 2018 Dec 18;13(12):e0208657. doi: 10.1371/journal.pone.0208657. eCollection 2018.

10.

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients.

Salmon D, Trimoulet P, Gilbert C, Solas C, Lafourcade E, Chas J, Piroth L, Lacombe K, Katlama C, Peytavin G, Aumaitre H, Alric L, Boué F, Morlat P, Poizot-Martin I, Billaud E, Rosenthal E, Naqvi A, Miailhes P, Bani-Sadr F, Esterle L, Carrieri P, Dabis F, Sogni P, Wittkop L; ANRS CO13 Hepavih study Group.

World J Hepatol. 2018 Nov 27;10(11):856-866. doi: 10.4254/wjh.v10.i11.856.

11.

Confirmation of HCV viremia using HCV RNA and core antigen testing on dried blood spot in HIV infected peoples who inject drugs in Vietnam.

Nguyen TT, Lemee V, Bollore K, Vu HV, Lacombe K, Thi XLT, Luong QA, Dubos C, Plantier JC, Thi HD, Laureillard D, Lemoine M, Tuaillon E.

BMC Infect Dis. 2018 Dec 4;18(1):622. doi: 10.1186/s12879-018-3529-3.

12.

Hepatitis B virus genotype G and liver fibrosis progression in chronic hepatitis B and human immunodeficiency virus coinfection.

Malagnino V, Bottero J, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F, Lacombe K, Boyd A.

J Med Virol. 2019 Apr;91(4):630-641. doi: 10.1002/jmv.25360. Epub 2018 Dec 3.

PMID:
30431661
13.

Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.

Grebely J, Conway B, Cunningham EB, Fraser C, Moriggia A, Gane E, Stedman C, Cooper C, Castro E, Schmid P, Petoumenos K, Hajarizadeh B, Marks P, Erratt A, Dalgard O, Lacombe K, Feld JJ, Bruneau J, Daulouede JP, Powis J, Bruggmann P, Matthews GV, Kronborg I, Shaw D, Dunlop A, Hellard M, Applegate TL, Crawford S, Dore GJ; D3FEAT Study Group.

Int J Drug Policy. 2018 Dec;62:94-103. doi: 10.1016/j.drugpo.2018.10.004. Epub 2018 Oct 29.

PMID:
30384028
14.

Occult Hepatitis B Virus Infection: An Old Entity With Novel Clinical Involvements.

Malagnino V, Fofana DB, Lacombe K, Gozlan J.

Open Forum Infect Dis. 2018 Sep 14;5(10):ofy227. doi: 10.1093/ofid/ofy227. eCollection 2018 Oct.

15.

HCV core antigen: toward elimination of nucleic acid testing?

Lemoine M, Lacombe K.

Lancet Gastroenterol Hepatol. 2018 Dec;3(12):817-818. doi: 10.1016/S2468-1253(18)30305-4. Epub 2018 Sep 28. No abstract available.

PMID:
30274835
16.

Self-reported patient history to assess hepatitis B virus serological status during a large screening campaign.

Boyd A, Gozlan J, Carrat F, Rougier H, Girard PM, Lacombe K, Bottero J.

Epidemiol Infect. 2018 Sep 28:1-8. doi: 10.1017/S0950268818002650. [Epub ahead of print]

17.

Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.

Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Danel C, Delaugerre C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study.

Liver Int. 2019 Feb;39(2):280-289. doi: 10.1111/liv.13975. Epub 2018 Oct 17.

18.

Risk of hepatocellular carcinoma after DAA treatment in cirrhotic HIV-HCV-coinfected patients: where do we stand?

Lacombe K.

AIDS. 2018 Jul 17;32(11):1533-1534. doi: 10.1097/QAD.0000000000001823. No abstract available.

PMID:
29957724
19.

Reply to Hector et al.

Kouamé GM, Boyd A, Moh R, Eholié SP, Danel C, Lacombe K, Anglaret X.

Clin Infect Dis. 2018 Sep 28;67(8):1311-1312. doi: 10.1093/cid/ciy307. No abstract available.

PMID:
29912299
20.

Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals.

Peters L, Laut K, Resnati C, Del Campo S, Leen C, Falconer K, Trofimova T, Paduta D, Gatell J, Rauch A, Lacombe K, Domingo P, Chkhartishvili N, Zangerle R, Matulionyte R, Mitsura V, Benfield T, Zilmer K, Khromova I, Lundgren J, Rockstroh J, Mocroft A; EuroSIDA Study Group.

AIDS. 2018 Sep 10;32(14):1995-2004. doi: 10.1097/QAD.0000000000001928.

21.

Precore G1896A mutation is associated with reduced rates of HBsAg seroclearance in treated HIV hepatitis B virus co-infected patients from Western Africa.

Boyd A, Moh R, Maylin S, Abdou Chekaraou M, Mahjoub N, Gabillard D, Anglaret X, Eholié SP, Delaugerre C, Danel C, Zoulim F, Lacombe K; ANRS 12240 VarBVA study.

J Viral Hepat. 2018 Oct;25(10):1121-1131. doi: 10.1111/jvh.12914. Epub 2018 May 9.

PMID:
29660214
22.

Twenty-Year Evolution of Hepatitis B Virus and Human Immunodeficiency Virus Prevalence and Incidence in Voluntary Blood Donors in Côte d'Ivoire.

Seri B, Minga A, Gabillard D, Dembele B, Konate S, Le Carrou J, Dohoun L, Abo Y, Karcher S, Coffie P, N'Dri-Yoman T, Attia A, Eholié SP, Danel C, Lacombe K, Anglaret X, Boyd A.

Open Forum Infect Dis. 2018 Mar 16;5(4):ofy060. doi: 10.1093/ofid/ofy060. eCollection 2018 Apr.

23.

Research gaps in viral hepatitis.

Boyd A, Duchesne L, Lacombe K.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25054. doi: 10.1002/jia2.25054.

24.

Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era.

Sacks-Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051.

25.

The Rocky Road to viral hepatitis elimination: assuring access to antiviral therapy for ALL coinfected patients from low- to high-income settings.

Lacombe K, Klein MB.

J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25073. doi: 10.1002/jia2.25073. No abstract available.

26.

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study.

Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M.

Clin Infect Dis. 2018 Sep 14;67(7):1010-1017. doi: 10.1093/cid/ciy220.

27.

CD4+ T Cell Recovery and Hepatitis B Virus Coinfection in HIV-Infected Patients from Côte d'Ivoire Initiating Antiretroviral Therapy.

Houghtaling L, Moh R, Abdou Chekaraou M, Gabillard D, Anglaret X, Eholié SP, Zoulim F, Danel C, Lacombe K, Boyd A.

AIDS Res Hum Retroviruses. 2018 May;34(5):439-445. doi: 10.1089/AID.2017.0272. Epub 2018 Mar 20.

PMID:
29466862
28.

Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.

Peters L, Mocroft A, Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K, De Wit S, Rockstroh J, Smidt J, Karpov I, Grzeszczuk A, Haziosmanovic V, Gottfredsson M, Radoi R, Kuzovatova E, Orkin C, Ridolfo AL, Zapirain J, Lundgren J.

Antivir Ther. 2018;23(5):405-413. doi: 10.3851/IMP3218.

PMID:
29303483
29.

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

Rosenthal E, Fougerou-Leurent C, Renault A, Carrieri MP, Marcellin F, Garraffo R, Teicher E, Aumaitre H, Lacombe K, Bailly F, Billaud E, Chevaliez S, Dominguez S, Valantin MA, Reynes J, Naqvi A, Cotte L, Metivier S, Leroy V, Dupon M, Allegre T, De Truchis P, Jeantils V, Chas J, Salmon-Ceron D, Morlat P, Neau D, Perré P, Piroth L, Pol S, Bourlière M, Pageaux GP, Alric L, Zucman D, Girard PM, Poizot-Martin I, Yazdanpanah Y, Raffi F, Pabic EL, Tual C, Pailhé A, Amri I, Bellissant E, Molina JM; ANRS HC31 SOFTRIH Study Group.

HIV Med. 2018 Mar;19(3):227-237. doi: 10.1111/hiv.12571. Epub 2017 Dec 7.

PMID:
29214737
30.

Risk of Rotavirus Nosocomial Spread After Inpatient Pentavalent Rotavirus Vaccination.

Hofstetter AM, Lacombe K, Klein EJ, Jones C, Strelitz B, Jacobson E, Ranade D, Ward ML, Mijatovic-Rustempasic S, Evans D, Wikswo M, Bowen MD, Parashar UD, Payne DC, Englund JA.

Pediatrics. 2018 Jan;141(1). pii: e20171110. doi: 10.1542/peds.2017-1110. Epub 2017 Dec 6.

31.

Low incidence of precore W28* mutant variants in treated hepatitis B virus and human immunodeficiency virus co-infected patients.

Boyd A, Lacombe K, Lavocat F, Miailhes P, Lascoux-Combe C, Girard PM, Zoulim F.

Antiviral Res. 2018 Jan;149:174-178. doi: 10.1016/j.antiviral.2017.11.014. Epub 2017 Nov 21.

PMID:
29169914
32.

Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa.

Boyd A, Houghtaling L, Moh R, Chekaraou MA, Gabillard D, Eholié SP, Anglaret X, Zoulim F, Danel C, Lacombe K, For The Anrs Trivacan And Anrs VarBVA Studies.

Am J Trop Med Hyg. 2017 Dec;97(6):1936-1942. doi: 10.4269/ajtmh.16-1016. Epub 2017 Oct 26.

33.

Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings.

Duchesne L, Lacombe K.

J Viral Hepat. 2018 Feb;25(2):108-117. doi: 10.1111/jvh.12827. Epub 2017 Dec 27. Review.

PMID:
29134742
34.

The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.

Carrieri MP, Protopopescu C, Marcellin F, Wittkop L, Lacombe K, Esterle L, Sogni P, Salmon-Ceron D; ANRS CO13 HEPAVIH Study Group.

J Hepatol. 2018 Apr;68(4):845-847. doi: 10.1016/j.jhep.2017.10.025. Epub 2017 Nov 2. No abstract available.

PMID:
29104123
35.

Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons.

Boyd A, Bottero J, Carrat F, Gozlan J, Rougier H, Girard PM, Lacombe K.

World J Gastroenterol. 2017 Oct 14;23(38):7037-7046. doi: 10.3748/wjg.v23.i38.7037.

36.

Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.

Kouamé GM, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, Ntakpe JB, Emième A, Maylin S, Chekaraou MA, Eholié SP, Zoulim F, Lacombe K, Anglaret X, Danel C; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 12136 Temprano and ANRS 12240 VarBVA Study Groups.

Clin Infect Dis. 2018 Jan 6;66(1):112-120. doi: 10.1093/cid/cix747.

PMID:
29020361
37.

Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients.

Boyd A, Canini L, Gozlan J, Lascoux-Combe C, Miailhes P, Fonquernie L, Girard PM, Lacombe K.

J Clin Virol. 2017 Oct;95:55-60. doi: 10.1016/j.jcv.2017.08.008. Epub 2017 Aug 25.

PMID:
28869890
38.

Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients.

Lemoine M, Lacombe K, Bastard JP, Sébire M, Fonquernie L, Valin N, Fellahi S, Capeau J, Girard PM, Meynard JL.

AIDS. 2017 Sep 10;31(14):1955-1964. doi: 10.1097/QAD.0000000000001587. Erratum in: AIDS. 2018 Aug 24;32(13):1909-1910.

39.

Diagnostic accuracy of the Coopscore© to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection.

Taibi L, Boyd A, Bosselut N, Bottero J, Guéchot J, Lacombe K, Lasnier E, Baudin B, Vaubourdolle M.

Ann Clin Biochem. 2018 Mar;55(2):236-243. doi: 10.1177/0004563217707979. Epub 2017 Jun 29.

PMID:
28661201
40.

HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study.

Duchesne L, Njouom R, Lissock F, Tamko-Mella GF, Rallier S, Poiteau L, Soulier A, Chevaliez S, Vernet G, Rouveau N, Pawlotsky JM, Girard PM, Lacombe K.

J Int AIDS Soc. 2017 May 15;20(1):21446. doi: 10.7448/IAS.20.1.21446.

41.

Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.

Griesbeck M, Valantin MA, Lacombe K, Samri-Hassimi A, Bottero J, Blanc C, Sbihi Z, Zoorob R, Katlama C, Guiguet M, Altfeld M, Autran B; HepACT-VIH study group.

AIDS. 2017 Jun 1;31(9):1223-1234. doi: 10.1097/QAD.0000000000001455.

PMID:
28492391
42.

Estimating the Time to Diagnosis and the Chance of Spontaneous Clearance During Acute Hepatitis C in Human Immunodeficiency Virus-Infected Individuals.

Ragonnet R, Deuffic-Burban S, Boesecke C, Guiguet M, Lacombe K, Guedj J, Rockstroh JK, Yazdanpanah Y.

Open Forum Infect Dis. 2017 Jan 31;4(1):ofw235. doi: 10.1093/ofid/ofw235. eCollection 2017 Winter.

43.

Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

Boyd A, Bottero J, Miailhes P, Lascoux-Combe C, Rougier H, Girard PM, Serfaty L, Lacombe K.

J Int AIDS Soc. 2017 Feb 28;20(1):21426. doi: 10.7448/IAS.20.1.21426.

44.

Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.

Lacombe K, Fontaine H, Dhiver C, Metivier S, Rosenthal E, Antonini T, Valantin MA, Miailhes P, Harent S, Batisse D, Pageaux GP, Chas J, Aumaitre H, Dominguez S, Allegre T, Lafeuillade A, Billaud E, De Truchis P, Perre P, Leroy V, De Ledinghen V, Sogni P, Dabis F, Zhao Y, Filipovics A, Fedchuk L, Akremi R, Bennai Y, Salmon Ceron D.

J Acquir Immune Defic Syndr. 2017 May 1;75(1):97-107. doi: 10.1097/QAI.0000000000001342.

45.

First Report of CD4 Lymphopenia and Defective Neutrophil Functions in a Patient with Amebiasis Associated with CMV Reactivation and Severe Bacterial and Fungal Infections.

Ghrenassia E, Guihot A, Dong Y, Robinet P, Fontaine T, Lacombe K, Lescot T, Meyohas MC, Elbim C.

Front Microbiol. 2017 Feb 13;8:203. doi: 10.3389/fmicb.2017.00203. eCollection 2017.

46.

Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.

Piroth L, Wittkop L, Lacombe K, Rosenthal E, Gilbert C, Miailhes P, Carrieri P, Chas J, Poizot-Martin I, Gervais A, Dominguez S, Neau D, Zucman D, Billaud E, Morlat P, Aumaitre H, Lascoux-Combe C, Simon A, Bouchaud O, Teicher E, Bani-Sadr F, Alric L, Vittecoq D, Boué F, Duvivier C, Valantin MA, Esterle L, Dabis F, Sogni P, Salmon D; ANRS CO13 HEPAVIH study group.

J Hepatol. 2017 Jul;67(1):23-31. doi: 10.1016/j.jhep.2017.02.012. Epub 2017 Feb 22.

PMID:
28235612
47.

Potential effect of lamivudine-induced S gene mutations on liver-related pathogenesis in hepatitis D virus infection.

Boyd A, Miailhes P, Lacombe K, Zoulim F.

Hepatology. 2017 Apr;65(4):1424-1426. doi: 10.1002/hep.29062. Epub 2017 Mar 6. No abstract available.

PMID:
28103643
48.

HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.

Ingiliz P, Martin TC, Rodger A, Stellbrink HJ, Mauss S, Boesecke C, Mandorfer M, Bottero J, Baumgarten A, Bhagani S, Lacombe K, Nelson M, Rockstroh JK; NEAT study group.

J Hepatol. 2017 Feb;66(2):282-287. doi: 10.1016/j.jhep.2016.09.004. Epub 2016 Sep 17.

PMID:
27650285
49.

Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.

Boyd A, Miailhes P, Lascoux-Combe C, Rougier H, Girard PM, Plaisier E, Lacombe K.

Antivir Ther. 2017;22(1):31-42. doi: 10.3851/IMP3076. Epub 2016 Aug 24.

PMID:
27553871
50.

Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.

Boyd A, Piroth L, Maylin S, Maynard-Muet M, Lebossé F, Bouix C, Lascoux-Combe C, Mahjoub N, Girard PM, Delaugerre C, Carrat F, Lacombe K, Miailhes P.

J Viral Hepat. 2016 Dec;23(12):1017-1026. doi: 10.1111/jvh.12581. Epub 2016 Aug 3.

PMID:
27486094

Supplemental Content

Loading ...
Support Center